WO2000001322A1 - Medical device with porous surface for controlled drug release and method of making the same - Google Patents

Medical device with porous surface for controlled drug release and method of making the same Download PDF

Info

Publication number
WO2000001322A1
WO2000001322A1 PCT/US1999/015237 US9915237W WO0001322A1 WO 2000001322 A1 WO2000001322 A1 WO 2000001322A1 US 9915237 W US9915237 W US 9915237W WO 0001322 A1 WO0001322 A1 WO 0001322A1
Authority
WO
WIPO (PCT)
Prior art keywords
biologically active
active agent
suspension
solution
voids
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US1999/015237
Other languages
English (en)
French (fr)
Inventor
Ni Ding
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Schneider USA Inc
Original Assignee
Schneider USA Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schneider USA Inc filed Critical Schneider USA Inc
Priority to CA002336650A priority Critical patent/CA2336650C/en
Priority to JP2000557770A priority patent/JP2002519139A/ja
Priority to EP99932279A priority patent/EP1096902B1/en
Priority to DE1096902T priority patent/DE1096902T1/de
Priority to DE69938047T priority patent/DE69938047D1/de
Publication of WO2000001322A1 publication Critical patent/WO2000001322A1/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
    • A61F2/82—Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
    • A61L31/08—Materials for coatings
    • A61L31/10—Macromolecular materials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
    • A61L31/14—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • A61L31/146—Porous materials, e.g. foams or sponges
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
    • A61L31/14—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • A61L31/16—Biologically active materials, e.g. therapeutic substances
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
    • A61F2/02—Prostheses implantable into the body
    • A61F2/04—Hollow or tubular parts of organs, e.g. bladders, tracheae, bronchi or bile ducts
    • A61F2/06—Blood vessels
    • A61F2/07—Stent-grafts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2250/00—Special features of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof
    • A61F2250/0058—Additional features; Implant or prostheses properties not otherwise provided for
    • A61F2250/0067—Means for introducing or releasing pharmaceutical products into the body
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/20—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials
    • A61L2300/23—Carbohydrates
    • A61L2300/236—Glycosaminoglycans, e.g. heparin, hyaluronic acid, chondroitin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
    • A61L2300/42—Anti-thrombotic agents, anticoagulants, anti-platelet agents

Definitions

  • This invention relates generally to medical devices for delivering a biologically active agent or drug to a desired location within the body of a patient. More particularly, the invention is directed to medical devices having a porous surface comprising a plurality of voids therein.
  • the porous surface is capable of being loaded with a drug, e .g. , by infusing or placing the drug into the voids, for release into the body, particularly upon expansion of the portion of the medical device with the porous surface.
  • the drug is concentrated into the voids by electrophoresis.
  • the drug be directly applied to the diseased tissue. Because such localized delivery to the afflicted area usually requires a relatively small amount of drug, side effects of the drug are reduced. Also, since localized delivery requires smaller amounts of drugs, such delivery is desirable for expensive drugs.
  • a drug or biologically active agent is biologically derived (e.g., a gene, a protein or a ⁇ ipid)
  • it usually cannot withstand standard sterilization of the device e.g., ETO, gamma, or e-beam sterilization, autoclaving
  • standard sterilization of the device e.g., ETO, gamma, or e-beam sterilization, autoclaving
  • the number of drugs that can be incorporated into the implantable device is limited.
  • a number of methods for delivering drugs to body lumens or vessels involve the use of catheters having expandable portions, such as a balloon, disposed on the catheter.
  • hydrogel coated devices have certain disadvantages.
  • the loading of the drug into the hydrogel is based on diffusion, the amount of drug that can be loaded onto the devices is limited.
  • a composition of a drug, a polymeric material and a solvent is applied to at least a surface of the device.
  • a method is described in co-pending application serial No. 08/633,490, filed June 13, 1996 and published as EP 0 822 788A2 on February 11, 1998.
  • U.S. Patent No. 5,464,650 to Berg et al . describes drug containing coatings for medical devices.
  • the medical devices of the invention comprise a portion which has a porous surface.
  • the porous surface includes the pores and the material between the pores which make up the porous surface.
  • the porous surface is made of a material, such as polymer or a polymer blend, having a plurality of voids therein.
  • the void space of the coating is preferably greater than about 60% of the volume of the porous surface.
  • the porous surface can be a porous coating covering the surface of the device.
  • the thickness of such a coating can be tailored to meet individual needs for release of at least one biologically active agent.
  • the porous surface can be a structural part of the device.
  • a stent graft formed of a porous membrane would have a porous surface.
  • a biologically active agent is loaded into the voids for release when the device is implanted.
  • the medical device is a stent endoprosthesis having at least a portion which is covered with a polymeric porous surface such as a polymeric coating or material with a plurality of voids therein.
  • a biologically active agent or a drug is placed into the voids for controlled release when the stent is implanted or inserted into a body lumen.
  • the medical device is a stent graft comprising at least one portion which is made of porous graft material, which can, but need not be further covered with a porous or "sponge" coating.
  • a drug is loaded into the voids to form a drug-coated stent graft.
  • the devices of the present invention can be prepared by applying a porous coating composition to a surface of the device, e.g., stent or stent graft.
  • the porous coating composition comprises a polymer dissolved in a solvent and an elutable particulate material.
  • the porous surface or coating can be loaded with a drug in an electrophoresis method.
  • the drug is dissolved or suspended in a solvent to form a drug solution or suspension.
  • the device and an electrode are placed into the solution or suspension.
  • An electric current source e.g., battery, is connected to the device and the electrode.
  • the drug which has a positive or negative charge
  • the porous surface of the device can already contain materials which do not dissolve in the solution or suspension. Such materials include drugs or radiopaque materials, which permit the device to be visible during implantation under fluoroscopy.
  • porous stent graft With certain devices which are formed of porous materials, such as a porous stent graft, such devices can be loaded without first applying a porous coating to the graft. However, a porous coating can be used in conjunction with this type of device. A device with such a porous surface can be directly loaded in an electrophoresis method as described above.
  • Figures la-lb depict a method of preparing a porous coating for a medical device.
  • Figure 2 depicts an electrophoresis method for concentrating a biologically active agent into the porous coating or material.
  • Devices which can be used in this invention include self-expanding stents and balloon expandable stents.
  • self-expanding stents useful in the present invention are illustrated in U.S. Patent Nos. 4,655,771 and 4,954,126 issued to Wallsten and 5,061,275 issued to Wallsten et al .
  • Examples of appropriate balloon-expandable stents are shown in U.S. Patent No. 4,733,665 issued to Palmaz, U.S. Patent No. 4,800,882 issued to Gianturco and U.S. Patent No. 4,886,062 issued to Wiktor. It will be appreciated that all references cited herein are incorporated by reference in their entireties, for all purposes.
  • the expandable stent may be formed from polymeric, metallic, ceramic materials and/or composite materials. However, it is preferred that the stent contain a metallic material, e.g., stainless steel, nitinol, tantalum. Suitable polymeric materials include without limitation poly-L-lactic acid, polycarbonate and polyethylene terephthalate.
  • the stent grafts suitable for the present invention include those appropriate for cardiovascular applications, such as ones described in U.S. Patent No. 4,657,544 to Pinchuk, or urinary applications, such as U.S. Patent No. 4,334,327 to Lyman.
  • grafts are made of biocompatible polymeric materials, e.g., polyurethane, silicone, polyethylene terephthalate, teflon, or tissue engineered autografts or xenografts.
  • the graft include some metallic material to conduct the current and facilitate the concentrating of the drug into the porous surface.
  • the stent graft can be formed of a porous material having a porous surface, such as a porous membrane. Examples of such stent grafts and methods for making them are described in U.S. Patent No. 4,657,544 to Pinchuk and U.S. Patent No. 5,758,562 to Thompson.
  • porous stent grafts When such porous stent grafts are used in the electrophoresis method, they can, but do not have to be coated with a porous coating before the grafts are loaded with biologically active agents.
  • other implantable medical devices such as blood oxygenator, heart valves and vein valves can be used in the invention. In general, any implantable device that contains some metal portion can be used.
  • the polymer (s) useful for forming the porous coating should be ones that are biostable, biocompatible, particularly during insertion or implantation of the device into the body and avoids irritation to body tissue.
  • examples of such polymers include without limitation polyurethanes, polyisobutylene and its copolymers, silicones, and polyesters.
  • polystyrene resins include polyolefins, polyisobutylene, ethylene-alphaolefin copolymers, acrylic polymers and copolymers, vinyl halide polymers and copolymers such as polyvinyl chloride, polyvinyl ethers such as polyvinyl methyl ether, polyvinylidene halides such as polyvinylidene fluoride and polyvinylidene chloride, polyacrylonitrile, polyvinyl ketones, polyvinyl aromatics such as polystyrene, polyvinyl esters such as polyvinyl acetate; copolymers of vinyl monomers, copolymers of vinyl monomers, and olefins such as ethylene-methyl methacrylate copolymers, acrylonitrile-styrene copolymers, ABS resins, ethylene-vinyl acetate copolymers, polyamides such as Nylon 66 and polycaprolactone, alkyd resins,
  • the polymers are preferably selected from elastomeric polymers such as silicones (e.g., polysiloxanes and substituted polysiloxanes) , polyurethanes, thermoplastic elastomers, polyisobutylene and its copolymers ethylene vinyl acetate copolymers, polyolefin elastomers, and EPDM rubbers.
  • silicones e.g., polysiloxanes and substituted polysiloxanes
  • polyurethanes e.g., polysiloxanes and substituted polysiloxanes
  • thermoplastic elastomers e.g., polyisobutylene and its copolymers ethylene vinyl acetate copolymers
  • polyolefin elastomers elastomers
  • EPDM rubbers elastomeric rubbers
  • porous or sponge coating can be formed by using a single type of polymer, various combinations of polymers can be employed.
  • the appropriate mixture of polymers can be coordinated with biologically active agents of interest to produce desired effects when coated on a medical device in accordance with the invention.
  • the elutable particulate materials which can be incorporated into the polymer include without limitation polyethylene oxide, polyethylene glycol, polyethylene oxide/polypropylene oxide copolymers, polyhydroxyethyl methacrylate, polyvinylpyrrolidone, polyacrylamide and its copolymers, salts, e.g., sodium chloride, sugars, and elutable biologically active agents such as heparin.
  • the amount of elutable particulate material that is incorporated into the polymer should range from about 10% to 90% by weight of the porous or sponge coating and preferably, from about 30% to 70%.
  • the average particle size of the elutable material can range from 1-100 microns and preferably from about 2 to 15 microns.
  • the solvent that is used to form the mixture or slurry of polymer and elutable particulate materials include ones which can dissolve the polymer into solution and do not alter or adversely impact the therapeutic properties of the material employed.
  • useful solvents for silicone include tetrahydrofuran (THF) , chloroform and dichloromethane.
  • the composition of polymer and elutable particulate material can be applied to a portion of the medical device in a variety of ways.
  • the composition can be spray-coated onto the device or the device can be dipped into the composition.
  • One of skill in the art would be aware of methods for applying the coating to the device.
  • the thickness of the porous coating can range from about 10 ⁇ m to 0.5 mm. Preferably, the thickness is about 20 ⁇ m to 100 ⁇ m.
  • Certain polymers such as silicone can be cured at relatively low temperatures, (e.g., room temperature) in what is known as a room temperature vulcanization (RTV) process. More , typically, the curing/evaporation process involves higher temperatures so that the coated device is heated in a oven. Typically, the heating occurs at approximately 90°C or higher for approximately 1 to 16 hours when silicone is used. For certain coatings the heating may occur at temperatures as high as 150°C. The time and temperature of heating will of course vary with the particular polymer, drugs, and solvents used. One of skill in the art is aware of the necessary adjustments to these parameters.
  • RTV room temperature vulcanization
  • a solvent is used to elute the particulate material from the polymer.
  • the device can be soaked in the solvent to elute the particulate materials.
  • Other methods of eluting the particulate is apparent to those skilled in the art.
  • the choice of the solvent depends upon the solubility of the elutable particulate material in that solvent. For instance, for water-soluble particulate materials such as heparin, water can be used.
  • organic solvents can be used for elutable particulate materials which can be dissolved in organic solvents. Examples of suitable solvents, without limitation, include ethanol, dimethyl sulfoxide, etc.
  • a mixture or slurry comprising a polymer 101, an elutable particulate material 102 and a solvent is applied to a portion of the medical device.
  • the device is then exposed to an aqueous or organic solvent to elute the particulate material 102 from the polymer 101 to form a plurality of voids 103 in the polymer 101 ( Figure lb) .
  • phase inversion methods are: 1) solvent freeze drying; 2) polymer, solvent and non-solvent pore former systems; and 3) thermal processes using a latent solvent. A more detailed description of these methods can be found in R.E. Resting "Synthetic Polymeric Membranes - A
  • the medical device can be optionally sterilized. Depending upon the nature of the drug used, sterilization of the device can occur before or after the drug is loaded into the sponge coating. Methods of sterilization are known in the art. For example, the devices can be sterilized by exposure to gamma radiation at 2.5-3.5 Mrad or by exposure to ethylene oxide.
  • the porous materials or membranes which can be used to form porous stent graft can be made of a polymer. Suitable polymers include polyurethane, silicone, polytetra fluorethylene, polyethylene terephthalate, polyisobutylene and its copolymers, polylactic acid, polyglycolic acid and its copolymers, cellulose and its derivatives. Graft materials can also be biologically derived. For example, collagen, elastin, tissue engineered autografts or xenografts are suitable.
  • the stent graft contain some metallic material to facilitate loading of the coating with a drug by electrophoresis.
  • metallic material can be incorporated by laminating or cladding a metal or an metallic alloy onto the porous graft material.
  • an electrophoresis method can be used to load the biologically active agent in the porous surface. Specifically, as described in Figure 2, a graft or other medical device 10 having a porous surface 11 containing voids 12 is placed into a container 15 which holds a solution or a suspension 13 of a drug 14. The drug 14 does not have to be dissolved in a solvent. It can remain as a suspension such as a slurry.
  • an electrode 16 typically made of metal.
  • the electrode 16 and the device 10 with the porous surface 11 are connected, typically by wires 17 to a current source 18, such as a battery.
  • a current source 18 such as a battery.
  • the current source 18 is switched on, at least some of the drug 14, which contains either a positive or negative charge, is loaded into the voids 12 , thereby increasing the amount of the drug at the porous surface.
  • the drug 14 is negatively charged, e.g., a protein or heparin, the device 10 will function as an anode. If the drug 14 is positively charged, the device 10 will function as a cathode.
  • the type of electrode 16, i.e., its material, used will depend upon whether the device 10 functions as an anode or cathode. For example, if the device 10 is an anode, an electrode 16 which can function as a cathode is used. Persons skilled in the art are aware of how to select suitable electrodes 16.
  • the mobility of the drug 14 under the electric current can be varied. Specifically, at different pH levels, the predominant ionic form of the drug 14 will be different.
  • the pH of the solution or suspension 13 is low, e.g., acidic, the carboxyl group is un-ionized and the amino group is ionized.
  • amino acids are placed into a solution or suspension 13 with a high pH level, the carboxyl group is ionized and the amino group is un-ionized.
  • Such changes in the ionic form or charge form of the drug 14 affects its mobility under the electric current.
  • the porous surface of the device can contain some biologically active agent even before the surface is loaded with the drug 14 according to this method. More specifically, prior to placing the devices into the drug solution or suspension 13 the porous surface may already contain materials, such as particulate materials, that provide desirable properties to the device. These materials should not be soluble or elutable in the solvent forming the drug solution or suspension 13. They can include another biologically active agent or radiopaque materials to allow the device to be visible during implantation under fluoroscopy. As used herein, "biologically active agent" or
  • drug refers not only to the molecular or charged form of the biologically active agent or drug but also to formulations containing the same, such as, without limitation, liposomes, emulsions with surfactant and cyclodextrin encapsulations.
  • biologically active agents having an electric charge are used in this invention.
  • a neutral or a weakly charged biologically active agent can also be used if it can be converted to a charged moiety.
  • a neutral or a weakly charged biologically active agent can also be used if it can be converted to a charged moiety.
  • a neutral or a weakly charged biologically active agent can also be used if it can be converted to a charged moiety.
  • a neutral or a weakly charged biologically active agent can also be used if it can be converted to a charged moiety.
  • surfactants which can be used are, without limitation, fatty acids, phospholipids and sodium cetyl sulfate.
  • the biologically active agent can be converted to a charged moiety by cyclodextrin encapsulation.
  • Suitable biologically active agents include without limitation glucocorticoids (e.g., dexamethasone, beta ethasone) , heparin, hirudin, angiopeptin, aspirin, growth factors, oligonucleotides, and, more generally, antiplatelet agents, anti-coagulant agents, antimitotic agents, antioxidants, antimetabolite agents, anti-cancer agents and anti- inflammatory agents could be used.
  • Antiplatelet agents can include drugs such as aspirin. Aspirin is classified as an analgesic, antipyretic, anti-inflammatory and antiplatelet drug.
  • Anticoagulant agents can include drugs such as glycosa inoglycan, protamine, hirudin and tick anticoagulant protein.
  • Glycosaminoglycans include heparin, heparin sulfate, hyaluronic acid, chondroitin, chondroitin sulfate, dermatan sulfate and keratosulfate and their respective derivatives.
  • Antimitotic agents and antimetabolite agents can include drugs such as methotrexat .
  • Antibiotic agents can include penicillin, cefoxitin, and oxacillin.
  • genes or nucleic acids, or portions thereof can be used. Such genes or nucleic acids can first be packaged in liposomes or nanoparticles .
  • collagen synthesis inhibitors such as tranilast, can be used.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Surgery (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Cardiology (AREA)
  • Dispersion Chemistry (AREA)
  • Transplantation (AREA)
  • Oral & Maxillofacial Surgery (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Materials For Medical Uses (AREA)
  • Medicinal Preparation (AREA)
  • Media Introduction/Drainage Providing Device (AREA)
  • Prostheses (AREA)
PCT/US1999/015237 1998-07-07 1999-07-06 Medical device with porous surface for controlled drug release and method of making the same Ceased WO2000001322A1 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
CA002336650A CA2336650C (en) 1998-07-07 1999-07-06 Medical device with porous surface for controlled drug release and method of making the same
JP2000557770A JP2002519139A (ja) 1998-07-07 1999-07-06 薬剤の放出を制御するための多孔性表面をもつ医療用部材
EP99932279A EP1096902B1 (en) 1998-07-07 1999-07-06 Method of making a medical device with porous surface for controlled drug release
DE1096902T DE1096902T1 (de) 1998-07-07 1999-07-06 Medizinische einrichtung mit poröser oberfläche zur kontrollierten wirkstofffreigage und verfahren zu ihrer herstellung
DE69938047T DE69938047D1 (de) 1998-07-07 1999-07-06 Verfahren zur herstellung einer medizinischen einrichtung mit poröser oberfläche zur kontrollierten wirkstofffreigabe

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/110,697 1998-07-07
US09/110,697 US6652581B1 (en) 1998-07-07 1998-07-07 Medical device with porous surface for controlled drug release and method of making the same

Publications (1)

Publication Number Publication Date
WO2000001322A1 true WO2000001322A1 (en) 2000-01-13

Family

ID=22334400

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1999/015237 Ceased WO2000001322A1 (en) 1998-07-07 1999-07-06 Medical device with porous surface for controlled drug release and method of making the same

Country Status (8)

Country Link
US (3) US6652581B1 (https=)
EP (1) EP1096902B1 (https=)
JP (1) JP2002519139A (https=)
AT (1) ATE384502T1 (https=)
CA (1) CA2336650C (https=)
DE (2) DE69938047D1 (https=)
ES (1) ES2169012T1 (https=)
WO (1) WO2000001322A1 (https=)

Cited By (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002065946A1 (en) * 2001-02-23 2002-08-29 Angiogene Inc. Apparatus for loading a therapeutic agent onto an endovascular device
WO2002066092A3 (en) * 2001-02-23 2002-11-14 Angiogene Inc Drug eluting device for treating vascular diseases
WO2003039616A1 (en) * 2001-11-08 2003-05-15 Nihon University School Juridical Person Percutaneous transluminal drug delivery device
WO2005118016A1 (en) * 2004-05-27 2005-12-15 Medtronic, Inc. Medical device comprising a biologically active agent
US7125577B2 (en) 2002-09-27 2006-10-24 Surmodics, Inc Method and apparatus for coating of substrates
WO2006083904A3 (en) * 2005-02-01 2007-04-05 Boston Scient Scimed Inc Medical devices having porous polymeric regions for controlled drug delivery and regulated biocompatibility
US7294409B2 (en) 2002-11-13 2007-11-13 University Of Virgina Medical devices having porous layers and methods for making same
EP1217963A4 (en) * 1999-06-09 2007-12-12 Bard Inc C R DEVICES AND METHOD FOR TREATMENT OF TISSUE
WO2007108916A3 (en) * 2006-03-15 2007-12-27 Boston Scient Scimed Inc Drug delivery composition and methods of making same using nanofabrication
USRE40722E1 (en) 2002-09-27 2009-06-09 Surmodics, Inc. Method and apparatus for coating of substrates
US7713573B2 (en) 2002-11-13 2010-05-11 Medtronic Vascular, Inc. Method for loading nanoporous layers with therapeutic agent
US7776382B2 (en) 2002-09-27 2010-08-17 Surmodics, Inc Advanced coating apparatus and method
WO2011035220A1 (en) * 2009-09-20 2011-03-24 Medtronic Vascular Inc. Apparatus and methods for loading a drug eluting medical device
US7958840B2 (en) 2004-10-27 2011-06-14 Surmodics, Inc. Method and apparatus for coating of substrates
FR2983075A1 (fr) * 2011-11-24 2013-05-31 Ab7 Innovation Procede de chargement de plaquette polymere en solution medicamenteuse ionisee amphiphile pour administration transdermique par iontophorese
US8900292B2 (en) 2007-08-03 2014-12-02 Boston Scientific Scimed, Inc. Coating for medical device having increased surface area
US8916226B2 (en) 2009-09-20 2014-12-23 Medtronic Vascular, Inc. Method of forming hollow tubular drug eluting medical devices
US8920491B2 (en) 2008-04-22 2014-12-30 Boston Scientific Scimed, Inc. Medical devices having a coating of inorganic material
US8932346B2 (en) 2008-04-24 2015-01-13 Boston Scientific Scimed, Inc. Medical devices having inorganic particle layers
US9283350B2 (en) 2012-12-07 2016-03-15 Surmodics, Inc. Coating apparatus and methods
US9284409B2 (en) 2007-07-19 2016-03-15 Boston Scientific Scimed, Inc. Endoprosthesis having a non-fouling surface
US9283305B2 (en) 2009-07-09 2016-03-15 Medtronic Vascular, Inc. Hollow tubular drug eluting medical devices
US9308355B2 (en) 2012-06-01 2016-04-12 Surmodies, Inc. Apparatus and methods for coating medical devices
US9364349B2 (en) 2008-04-24 2016-06-14 Surmodics, Inc. Coating application system with shaped mandrel
US9421650B2 (en) 2010-09-17 2016-08-23 Medtronic Vascular, Inc. Method of forming a drug-eluting medical device
US9486340B2 (en) 2013-03-14 2016-11-08 Medtronic Vascular, Inc. Method for manufacturing a stent and stent manufactured thereby
US9770349B2 (en) 2002-11-13 2017-09-26 University Of Virginia Patent Foundation Nanoporous stents with enhanced cellular adhesion and reduced neointimal formation
US9827401B2 (en) 2012-06-01 2017-11-28 Surmodics, Inc. Apparatus and methods for coating medical devices
US11090468B2 (en) 2012-10-25 2021-08-17 Surmodics, Inc. Apparatus and methods for coating medical devices
US11628466B2 (en) 2018-11-29 2023-04-18 Surmodics, Inc. Apparatus and methods for coating medical devices
US11819590B2 (en) 2019-05-13 2023-11-21 Surmodics, Inc. Apparatus and methods for coating medical devices
US12496612B2 (en) 2021-01-08 2025-12-16 Surmodics, Inc. Coating application system and methods for coating rotatable medical devices

Families Citing this family (103)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU716005B2 (en) 1995-06-07 2000-02-17 Cook Medical Technologies Llc Implantable medical device
US6676626B1 (en) 1998-05-01 2004-01-13 Ekos Corporation Ultrasound assembly with increased efficacy
US6582392B1 (en) 1998-05-01 2003-06-24 Ekos Corporation Ultrasound assembly for use with a catheter
US7713297B2 (en) 1998-04-11 2010-05-11 Boston Scientific Scimed, Inc. Drug-releasing stent with ceramic-containing layer
US8177743B2 (en) 1998-05-18 2012-05-15 Boston Scientific Scimed, Inc. Localized delivery of drug agents
JP4854114B2 (ja) 1998-09-11 2012-01-18 シュミドマイヤー，ゲルハルド 生物学的に活性なインプラント
US20070032853A1 (en) 2002-03-27 2007-02-08 Hossainy Syed F 40-O-(2-hydroxy)ethyl-rapamycin coated stent
US7807211B2 (en) * 1999-09-03 2010-10-05 Advanced Cardiovascular Systems, Inc. Thermal treatment of an implantable medical device
US7682647B2 (en) 1999-09-03 2010-03-23 Advanced Cardiovascular Systems, Inc. Thermal treatment of a drug eluting implantable medical device
US8632845B2 (en) * 2000-12-28 2014-01-21 Abbott Cardiovascular Systems Inc. Method of drying bioabsorbable coating over stents
US6544223B1 (en) * 2001-01-05 2003-04-08 Advanced Cardiovascular Systems, Inc. Balloon catheter for delivering therapeutic agents
US8277868B2 (en) * 2001-01-05 2012-10-02 Abbott Cardiovascular Systems Inc. Balloon catheter for delivering therapeutic agents
US7727221B2 (en) 2001-06-27 2010-06-01 Cardiac Pacemakers Inc. Method and device for electrochemical formation of therapeutic species in vivo
EP1453425B1 (en) 2001-12-03 2006-03-08 Ekos Corporation Catheter with multiple ultrasound radiating members
US7141044B2 (en) 2001-12-11 2006-11-28 Ekos Corporation Alternate site gene therapy
US8226629B1 (en) 2002-04-01 2012-07-24 Ekos Corporation Ultrasonic catheter power control
US6921371B2 (en) 2002-10-14 2005-07-26 Ekos Corporation Ultrasound radiating members for catheter
US20050079199A1 (en) * 2003-02-18 2005-04-14 Medtronic, Inc. Porous coatings for drug release from medical devices
AU2004213021B2 (en) * 2003-02-18 2010-12-09 Medtronic, Inc. Occlusion resistant hydrocephalic shunt
EP1449546B1 (en) * 2003-02-21 2010-10-27 Sorin Biomedica Cardio S.R.L. A process for producing stents and corresponding stent
EP1475110A1 (de) * 2003-05-09 2004-11-10 B. Braun Melsungen Ag Stent zur kontrollierten Abgabe von Wirkstoffen
US20050118344A1 (en) * 2003-12-01 2005-06-02 Pacetti Stephen D. Temperature controlled crimping
US20050137520A1 (en) * 2003-10-29 2005-06-23 Rule Peter R. Catheter with ultrasound-controllable porous membrane
US7803178B2 (en) 2004-01-30 2010-09-28 Trivascular, Inc. Inflatable porous implants and methods for drug delivery
DE602004027553D1 (de) * 2004-08-03 2010-07-15 Agency Science Tech & Res Polymer mit miteinander verbundenen poren zur arzneistoffzufuhr und verfahren
US7507433B2 (en) * 2004-09-03 2009-03-24 Boston Scientific Scimed, Inc. Method of coating a medical device using an electrowetting process
US20060051392A1 (en) * 2004-09-03 2006-03-09 Medtronic, Inc. Porous coatings for drug release from medical devices
US20060051393A1 (en) * 2004-09-08 2006-03-09 Medtronic, Inc. Method of manufacturing drug-eluting medical device
US7901451B2 (en) 2004-09-24 2011-03-08 Biosensors International Group, Ltd. Drug-delivery endovascular stent and method for treating restenosis
US7862835B2 (en) 2004-10-27 2011-01-04 Boston Scientific Scimed, Inc. Method of manufacturing a medical device having a porous coating thereon
US7964209B2 (en) 2004-12-07 2011-06-21 Boston Scientific Scimed, Inc. Orienting polymer domains for controlled drug delivery
US20060124466A1 (en) * 2004-12-09 2006-06-15 Scimed Life Systems, Inc. Method and apparatus for coating a medical device by electroplating
EP1893130A4 (en) 2005-06-17 2015-08-26 Georgia Tech Res Inst COATED MICROSTRUCTURES AND METHOD FOR THE PRODUCTION THEREOF
JP5063603B2 (ja) * 2005-09-30 2012-10-31 クック メディカル テクノロジーズ エルエルシー 被覆された血管閉塞装置
US20070112421A1 (en) * 2005-11-14 2007-05-17 O'brien Barry Medical device with a grooved surface
US8840660B2 (en) 2006-01-05 2014-09-23 Boston Scientific Scimed, Inc. Bioerodible endoprostheses and methods of making the same
US20070168021A1 (en) * 2006-01-17 2007-07-19 Holmes David R Jr Porous three dimensional nest scaffolding
US8089029B2 (en) 2006-02-01 2012-01-03 Boston Scientific Scimed, Inc. Bioabsorbable metal medical device and method of manufacture
US20070224235A1 (en) 2006-03-24 2007-09-27 Barron Tenney Medical devices having nanoporous coatings for controlled therapeutic agent delivery
US8187620B2 (en) 2006-03-27 2012-05-29 Boston Scientific Scimed, Inc. Medical devices comprising a porous metal oxide or metal material and a polymer coating for delivering therapeutic agents
US8048150B2 (en) 2006-04-12 2011-11-01 Boston Scientific Scimed, Inc. Endoprosthesis having a fiber meshwork disposed thereon
EP2020956A2 (en) 2006-05-26 2009-02-11 Nanyang Technological University Implantable article, method of forming same and method for reducing thrombogenicity
US8815275B2 (en) 2006-06-28 2014-08-26 Boston Scientific Scimed, Inc. Coatings for medical devices comprising a therapeutic agent and a metallic material
EP2032091A2 (en) 2006-06-29 2009-03-11 Boston Scientific Limited Medical devices with selective coating
US8052743B2 (en) 2006-08-02 2011-11-08 Boston Scientific Scimed, Inc. Endoprosthesis with three-dimensional disintegration control
US9248121B2 (en) * 2006-08-21 2016-02-02 Abbott Laboratories Medical devices for controlled drug release
JP2010503469A (ja) 2006-09-14 2010-02-04 ボストン サイエンティフィック リミテッド 薬物溶出性皮膜を有する医療デバイス
WO2008034048A2 (en) 2006-09-15 2008-03-20 Boston Scientific Limited Bioerodible endoprosthesis with biostable inorganic layers
WO2008034066A1 (en) 2006-09-15 2008-03-20 Boston Scientific Limited Bioerodible endoprostheses and methods of making the same
CA2663220A1 (en) 2006-09-15 2008-03-20 Boston Scientific Limited Medical devices and methods of making the same
US8808726B2 (en) 2006-09-15 2014-08-19 Boston Scientific Scimed. Inc. Bioerodible endoprostheses and methods of making the same
US8002821B2 (en) 2006-09-18 2011-08-23 Boston Scientific Scimed, Inc. Bioerodible metallic ENDOPROSTHESES
US7981150B2 (en) 2006-11-09 2011-07-19 Boston Scientific Scimed, Inc. Endoprosthesis with coatings
JP2010509988A (ja) * 2006-11-16 2010-04-02 ボストン サイエンティフィック リミテッド 治療薬を異なるタイミングで管外側および管腔側に放出するステント
EP2087020A4 (en) * 2006-11-17 2010-11-24 Agency Science Tech & Res POROUS POLYMERIC MATERIAL COMPRISING A CROSS-LINING AGENT
US20080152784A1 (en) * 2006-12-22 2008-06-26 Boston Scientific Scimed, Inc. Methods of manufacturing coatings and coated medical devices
WO2008083190A2 (en) 2006-12-28 2008-07-10 Boston Scientific Limited Bioerodible endoprostheses and methods of making same
CN101209360B (zh) * 2006-12-29 2012-06-20 微创医疗器械(上海)有限公司 一种生物支架的制备方法
US10182833B2 (en) 2007-01-08 2019-01-22 Ekos Corporation Power parameters for ultrasonic catheter
US8070797B2 (en) 2007-03-01 2011-12-06 Boston Scientific Scimed, Inc. Medical device with a porous surface for delivery of a therapeutic agent
US8431149B2 (en) 2007-03-01 2013-04-30 Boston Scientific Scimed, Inc. Coated medical devices for abluminal drug delivery
US8067054B2 (en) 2007-04-05 2011-11-29 Boston Scientific Scimed, Inc. Stents with ceramic drug reservoir layer and methods of making and using the same
EP2160483A2 (en) * 2007-04-12 2010-03-10 Boston Scientific Scimed, Inc. Methods and systems for applying therapeutic agent to a medical device
US7976915B2 (en) 2007-05-23 2011-07-12 Boston Scientific Scimed, Inc. Endoprosthesis with select ceramic morphology
EP2494932B1 (en) 2007-06-22 2020-05-20 Ekos Corporation Apparatus for treatment of intracranial hemorrhages
US7942926B2 (en) 2007-07-11 2011-05-17 Boston Scientific Scimed, Inc. Endoprosthesis coating
US8002823B2 (en) 2007-07-11 2011-08-23 Boston Scientific Scimed, Inc. Endoprosthesis coating
US7931683B2 (en) 2007-07-27 2011-04-26 Boston Scientific Scimed, Inc. Articles having ceramic coated surfaces
US8815273B2 (en) 2007-07-27 2014-08-26 Boston Scientific Scimed, Inc. Drug eluting medical devices having porous layers
WO2009018340A2 (en) 2007-07-31 2009-02-05 Boston Scientific Scimed, Inc. Medical device coating by laser cladding
US8052745B2 (en) 2007-09-13 2011-11-08 Boston Scientific Scimed, Inc. Endoprosthesis
US20090076591A1 (en) * 2007-09-19 2009-03-19 Boston Scientific Scimed, Inc. Stent Design Allowing Extended Release of Drug and/or Enhanced Adhesion of Polymer to OD Surface
US8216632B2 (en) 2007-11-02 2012-07-10 Boston Scientific Scimed, Inc. Endoprosthesis coating
US8029554B2 (en) 2007-11-02 2011-10-04 Boston Scientific Scimed, Inc. Stent with embedded material
US7938855B2 (en) 2007-11-02 2011-05-10 Boston Scientific Scimed, Inc. Deformable underlayer for stent
US7833266B2 (en) 2007-11-28 2010-11-16 Boston Scientific Scimed, Inc. Bifurcated stent with drug wells for specific ostial, carina, and side branch treatment
EP2594311A3 (en) * 2008-03-06 2013-07-10 Boston Scientific Scimed, Inc. Balloon catheter devices with sheath covering
US7998192B2 (en) 2008-05-09 2011-08-16 Boston Scientific Scimed, Inc. Endoprostheses
US8236046B2 (en) 2008-06-10 2012-08-07 Boston Scientific Scimed, Inc. Bioerodible endoprosthesis
US8449603B2 (en) 2008-06-18 2013-05-28 Boston Scientific Scimed, Inc. Endoprosthesis coating
US8206635B2 (en) 2008-06-20 2012-06-26 Amaranth Medical Pte. Stent fabrication via tubular casting processes
US8206636B2 (en) 2008-06-20 2012-06-26 Amaranth Medical Pte. Stent fabrication via tubular casting processes
US10898620B2 (en) 2008-06-20 2021-01-26 Razmodics Llc Composite stent having multi-axial flexibility and method of manufacture thereof
US7951193B2 (en) 2008-07-23 2011-05-31 Boston Scientific Scimed, Inc. Drug-eluting stent
US7985252B2 (en) 2008-07-30 2011-07-26 Boston Scientific Scimed, Inc. Bioerodible endoprosthesis
US8642063B2 (en) 2008-08-22 2014-02-04 Cook Medical Technologies Llc Implantable medical device coatings with biodegradable elastomer and releasable taxane agent
US8382824B2 (en) 2008-10-03 2013-02-26 Boston Scientific Scimed, Inc. Medical implant having NANO-crystal grains with barrier layers of metal nitrides or fluorides
US8231980B2 (en) 2008-12-03 2012-07-31 Boston Scientific Scimed, Inc. Medical implants including iridium oxide
WO2010101901A2 (en) 2009-03-02 2010-09-10 Boston Scientific Scimed, Inc. Self-buffering medical implants
US8071156B2 (en) 2009-03-04 2011-12-06 Boston Scientific Scimed, Inc. Endoprostheses
US8513353B2 (en) 2009-03-19 2013-08-20 Agency For Science, Technology And Research Forming copolymer from bicontinuous microemulsion comprising monomers of different hydrophilicity
US8287937B2 (en) 2009-04-24 2012-10-16 Boston Scientific Scimed, Inc. Endoprosthese
EP2470232B1 (en) * 2009-08-27 2016-03-30 Boston Scientific Scimed, Inc. Balloon catheter devices with drug-coated sheath
US8668732B2 (en) 2010-03-23 2014-03-11 Boston Scientific Scimed, Inc. Surface treated bioerodible metal endoprostheses
US20120022178A1 (en) * 2010-06-17 2012-01-26 Diversified Glogal Technologies, Llc Methods of embedding foam with additives
TW201315451A (zh) 2011-10-06 2013-04-16 Metal Ind Res & Dev Ct 金屬植入物表面處理方法及其金屬植入物
CN103757683B (zh) * 2014-01-07 2016-05-25 江南大学 一种光交联型生物基涂层的电沉积制备方法
WO2015119653A1 (en) 2014-02-04 2015-08-13 Abbott Cardiovascular Systems Inc. Drug delivery scaffold or stent with a novolimus and lactide based coating such that novolimus has a minimum amount of bonding to the coating
US9821090B2 (en) * 2014-09-30 2017-11-21 The Spectranetics Corporation Electrodeposition coating for medical devices
US9808608B2 (en) 2014-11-16 2017-11-07 International Business Machines Corporation Helical coil delivery device for active agent
WO2016201136A1 (en) 2015-06-10 2016-12-15 Ekos Corporation Ultrasound catheter
US11219436B2 (en) 2020-01-24 2022-01-11 PatchClamp Medtech, Inc. Tissue repair and sealing devices having a detachable graft and clasp assembly and methods for the use thereof
US11911572B2 (en) * 2022-05-05 2024-02-27 Innocare Urologics, Llc Soft tip drug-eluting urinary drainage catheter

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5304121A (en) * 1990-12-28 1994-04-19 Boston Scientific Corporation Drug delivery system making use of a hydrogel polymer coating
EP0747069A2 (en) * 1995-06-07 1996-12-11 Cook Incorporated Implantable medical device
US5607467A (en) * 1990-09-14 1997-03-04 Froix; Michael Expandable polymeric stent with memory and delivery apparatus and method
US5693085A (en) * 1994-04-29 1997-12-02 Scimed Life Systems, Inc. Stent with collagen

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3758396A (en) * 1971-08-31 1973-09-11 Research Corp Ition preparation of immobilized enzymemembrane complexes by electrocodepos
US4101984A (en) * 1975-05-09 1978-07-25 Macgregor David C Cardiovascular prosthetic devices and implants with porous systems
US4334327A (en) 1979-12-21 1982-06-15 University Of Utah Ureteral prosthesis
SE445884B (sv) 1982-04-30 1986-07-28 Medinvent Sa Anordning for implantation av en rorformig protes
US4657544A (en) 1984-04-18 1987-04-14 Cordis Corporation Cardiovascular graft and method of forming same
US4733665C2 (en) 1985-11-07 2002-01-29 Expandable Grafts Partnership Expandable intraluminal graft and method and apparatus for implanting an expandable intraluminal graft
SE453258B (sv) 1986-04-21 1988-01-25 Medinvent Sa Elastisk, sjelvexpanderande protes samt forfarande for dess framstellning
US4800882A (en) 1987-03-13 1989-01-31 Cook Incorporated Endovascular stent and delivery system
US4886062A (en) 1987-10-19 1989-12-12 Medtronic, Inc. Intravascular radially expandable stent and method of implant
US5073365A (en) * 1989-06-01 1991-12-17 Advanced Polymer Systems Clinical and personal care articles enhanced by lubricants and adjuvants
US5674192A (en) 1990-12-28 1997-10-07 Boston Scientific Corporation Drug delivery
US5120322A (en) 1990-06-13 1992-06-09 Lathrotec, Inc. Method and apparatus for treatment of fibrotic lesions
US5205921A (en) * 1991-02-04 1993-04-27 Queen's University At Kingston Method for depositing bioactive coatings on conductive substrates
US5147370A (en) * 1991-06-12 1992-09-15 Mcnamara Thomas O Nitinol stent for hollow body conduits
US5500013A (en) * 1991-10-04 1996-03-19 Scimed Life Systems, Inc. Biodegradable drug delivery vascular stent
US5464650A (en) 1993-04-26 1995-11-07 Medtronic, Inc. Intravascular stent and method
DE69623455T2 (de) 1995-04-19 2003-01-16 Schneider (Usa) Inc., Plymouth Beschichteter dilatator zur abgabe eines arzneistoffs
US5758562A (en) 1995-10-11 1998-06-02 Schneider (Usa) Inc. Process for manufacturing braided composite prosthesis
CA2199890C (en) * 1996-03-26 2002-02-05 Corvita Corporation Stents and stent-grafts having enhanced hoop strength and methods of making the same
US5843172A (en) * 1997-04-15 1998-12-01 Advanced Cardiovascular Systems, Inc. Porous medicated stent
US5972027A (en) * 1997-09-30 1999-10-26 Scimed Life Systems, Inc Porous stent drug delivery system
US6267782B1 (en) * 1997-11-20 2001-07-31 St. Jude Medical, Inc. Medical article with adhered antimicrobial metal
US6364856B1 (en) * 1998-04-14 2002-04-02 Boston Scientific Corporation Medical device with sponge coating for controlled drug release
US6635082B1 (en) * 2000-12-29 2003-10-21 Advanced Cardiovascular Systems Inc. Radiopaque stent

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5607467A (en) * 1990-09-14 1997-03-04 Froix; Michael Expandable polymeric stent with memory and delivery apparatus and method
US5304121A (en) * 1990-12-28 1994-04-19 Boston Scientific Corporation Drug delivery system making use of a hydrogel polymer coating
US5693085A (en) * 1994-04-29 1997-12-02 Scimed Life Systems, Inc. Stent with collagen
EP0747069A2 (en) * 1995-06-07 1996-12-11 Cook Incorporated Implantable medical device

Cited By (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1217963A4 (en) * 1999-06-09 2007-12-12 Bard Inc C R DEVICES AND METHOD FOR TREATMENT OF TISSUE
WO2002066092A3 (en) * 2001-02-23 2002-11-14 Angiogene Inc Drug eluting device for treating vascular diseases
WO2002065946A1 (en) * 2001-02-23 2002-08-29 Angiogene Inc. Apparatus for loading a therapeutic agent onto an endovascular device
WO2003039616A1 (en) * 2001-11-08 2003-05-15 Nihon University School Juridical Person Percutaneous transluminal drug delivery device
USRE46251E1 (en) 2002-09-27 2016-12-27 Surmodics, Inc. Advanced coating apparatus and method
US7125577B2 (en) 2002-09-27 2006-10-24 Surmodics, Inc Method and apparatus for coating of substrates
USRE40722E1 (en) 2002-09-27 2009-06-09 Surmodics, Inc. Method and apparatus for coating of substrates
US7669548B2 (en) 2002-09-27 2010-03-02 Surmodics, Inc. Method and apparatus for coating of substrates
US7776382B2 (en) 2002-09-27 2010-08-17 Surmodics, Inc Advanced coating apparatus and method
US9770349B2 (en) 2002-11-13 2017-09-26 University Of Virginia Patent Foundation Nanoporous stents with enhanced cellular adhesion and reduced neointimal formation
US7294409B2 (en) 2002-11-13 2007-11-13 University Of Virgina Medical devices having porous layers and methods for making same
US8449602B2 (en) 2002-11-13 2013-05-28 Medtronic Vascular, Inc. Methods for using a stent having nanoporous layers
US7713573B2 (en) 2002-11-13 2010-05-11 Medtronic Vascular, Inc. Method for loading nanoporous layers with therapeutic agent
US8124166B2 (en) 2002-11-13 2012-02-28 Medtronic Vascular, Inc. Method for loading nanoporous layers with therapeutic agent
US7699832B2 (en) 2004-05-27 2010-04-20 Medtronic, Inc. Medical device having a surface including a biologically active agent therein, and methods
WO2005118016A1 (en) * 2004-05-27 2005-12-15 Medtronic, Inc. Medical device comprising a biologically active agent
US7958840B2 (en) 2004-10-27 2011-06-14 Surmodics, Inc. Method and apparatus for coating of substrates
US8535702B2 (en) 2005-02-01 2013-09-17 Boston Scientific Scimed, Inc. Medical devices having porous polymeric regions for controlled drug delivery and regulated biocompatibility
WO2006083904A3 (en) * 2005-02-01 2007-04-05 Boston Scient Scimed Inc Medical devices having porous polymeric regions for controlled drug delivery and regulated biocompatibility
WO2007108916A3 (en) * 2006-03-15 2007-12-27 Boston Scient Scimed Inc Drug delivery composition and methods of making same using nanofabrication
US9284409B2 (en) 2007-07-19 2016-03-15 Boston Scientific Scimed, Inc. Endoprosthesis having a non-fouling surface
US8900292B2 (en) 2007-08-03 2014-12-02 Boston Scientific Scimed, Inc. Coating for medical device having increased surface area
US8920491B2 (en) 2008-04-22 2014-12-30 Boston Scientific Scimed, Inc. Medical devices having a coating of inorganic material
US9364349B2 (en) 2008-04-24 2016-06-14 Surmodics, Inc. Coating application system with shaped mandrel
US8932346B2 (en) 2008-04-24 2015-01-13 Boston Scientific Scimed, Inc. Medical devices having inorganic particle layers
US9283305B2 (en) 2009-07-09 2016-03-15 Medtronic Vascular, Inc. Hollow tubular drug eluting medical devices
WO2011035220A1 (en) * 2009-09-20 2011-03-24 Medtronic Vascular Inc. Apparatus and methods for loading a drug eluting medical device
US8916226B2 (en) 2009-09-20 2014-12-23 Medtronic Vascular, Inc. Method of forming hollow tubular drug eluting medical devices
CN102665782B (zh) * 2009-09-20 2014-07-09 麦德托尼克瓦斯科尔勒公司 将治疗物质加载到形成中空支架的中空线材的内腔空间内的方法
CN102665782A (zh) * 2009-09-20 2012-09-12 麦德托尼克瓦斯科尔勒公司 用于对药物洗脱医疗装置进行加载的设备和方法
US9421650B2 (en) 2010-09-17 2016-08-23 Medtronic Vascular, Inc. Method of forming a drug-eluting medical device
FR2983075A1 (fr) * 2011-11-24 2013-05-31 Ab7 Innovation Procede de chargement de plaquette polymere en solution medicamenteuse ionisee amphiphile pour administration transdermique par iontophorese
US9827401B2 (en) 2012-06-01 2017-11-28 Surmodics, Inc. Apparatus and methods for coating medical devices
US9623215B2 (en) 2012-06-01 2017-04-18 Surmodics, Inc. Apparatus and methods for coating medical devices
US9308355B2 (en) 2012-06-01 2016-04-12 Surmodies, Inc. Apparatus and methods for coating medical devices
US10099041B2 (en) 2012-06-01 2018-10-16 Surmodics, Inc. Apparatus and methods for coating medical devices
US10507309B2 (en) 2012-06-01 2019-12-17 Surmodics, Inc. Apparatus and methods for coating medical devices
US11090468B2 (en) 2012-10-25 2021-08-17 Surmodics, Inc. Apparatus and methods for coating medical devices
US9283350B2 (en) 2012-12-07 2016-03-15 Surmodics, Inc. Coating apparatus and methods
US9486340B2 (en) 2013-03-14 2016-11-08 Medtronic Vascular, Inc. Method for manufacturing a stent and stent manufactured thereby
US11628466B2 (en) 2018-11-29 2023-04-18 Surmodics, Inc. Apparatus and methods for coating medical devices
US11819590B2 (en) 2019-05-13 2023-11-21 Surmodics, Inc. Apparatus and methods for coating medical devices
US12496612B2 (en) 2021-01-08 2025-12-16 Surmodics, Inc. Coating application system and methods for coating rotatable medical devices

Also Published As

Publication number Publication date
JP2002519139A (ja) 2002-07-02
CA2336650A1 (en) 2000-01-13
EP1096902B1 (en) 2008-01-23
EP1096902A1 (en) 2001-05-09
US20040067301A1 (en) 2004-04-08
ATE384502T1 (de) 2008-02-15
ES2169012T1 (es) 2002-07-01
DE69938047D1 (de) 2008-03-13
US7758909B2 (en) 2010-07-20
CA2336650C (en) 2008-01-29
US6652581B1 (en) 2003-11-25
DE1096902T1 (de) 2002-05-23
US20070299509A1 (en) 2007-12-27

Similar Documents

Publication Publication Date Title
CA2336650C (en) Medical device with porous surface for controlled drug release and method of making the same
US6364856B1 (en) Medical device with sponge coating for controlled drug release
US8070797B2 (en) Medical device with a porous surface for delivery of a therapeutic agent
US8431149B2 (en) Coated medical devices for abluminal drug delivery
EP1180013B1 (en) Local drug delivery
JP4184961B2 (ja) 医療機器をスプレーコーティングするための方法
US8257729B2 (en) Implants with membrane diffusion-controlled release of active ingredient
JP2006500163A (ja) 医療器具にコーティングを施す方法
IL123622A (en) Process for coating a stent with a medicinal preparation is released
CN101820932A (zh) 释放铁离子的内置假体
US20070048433A1 (en) Coating of surgical devices
US20100183501A1 (en) Medical Devices With Nanotextured Titanium Coating
CA2579524A1 (en) Medical device with porous surface for controlled drug release and method of making the same
US20140379069A1 (en) Negatively charged vascular stent
US20090228089A1 (en) Full Thickness Porous Stent
CN113244029A (zh) 具有可生物降解层的支架

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): CA JP

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
ENP Entry into the national phase

Ref document number: 2336650

Country of ref document: CA

ENP Entry into the national phase

Ref country code: JP

Ref document number: 2000 557770

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 1999932279

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1999932279

Country of ref document: EP

WWG Wipo information: grant in national office

Ref document number: 1999932279

Country of ref document: EP